Related Experiment Video
Updated: Jul 5, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Small cell lung cancer with SYN2::PPARG fusion
M R Ghigna1, S Cotteret1, A Arbab1
1Gustave Roussy Department of Biopathology, 114 Rue Edouard Vaillant, Villejuif, FR 94805, France.
Introduction:
Small cell lung cancer (SCLC) accounts for 15% of lung cancers worldwide. It is an aggressive tumor that is typically diagnosed at an advanced stage. Treatment involves chemo-immunotherapy and/or radiotherapy. Identifying druggable targets activated by specific genetic alterations represents a significant challenge in improving patient outcomes.
Methods:
We conducted a retrospective examination of molecular findings in lung cancer patients' records from 2021 to 2022. We discovered a unique case of SCLC harboring the SYN2-PPARG fusion. Histopathological analysis confirmed the diagnosis of SCLC.
Case Report:
A 60-year-old woman, a heavy smoker, came to our attention due to a persistent cough with slight hemoptysis. Imaging, including axial contrast-enhanced computed tomography, revealed an advanced disease with extra-thoracic spread. Tumor histology showed a sheet-like proliferation of small-sized cells with a neuroendocrine phenotype and a high proliferation tumor cell fraction. Molecular genetic analysis using NGS approach revealed a fusion involving the SYN2 and PPARG genes.
Conclusion:
The SYN2-PPARG fusion has recently been documented in sinonasal adenocarcinoma and has been reported in only a single SCLC case previously. Highlighting the molecular heterogeneity within this aggressive form of lung cancer could potentially aid in the selection of specific therapies.
Insights
A rare SYN2-PPARG gene fusion was identified in a patient with advanced small cell lung cancer (SCLC). This finding highlights molecular diversity in SCLC, potentially guiding future targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy, often diagnosed at advanced stages.
- Current treatments include chemo-immunotherapy and radiotherapy.
- Identifying novel therapeutic targets in SCLC remains a critical challenge.
Observation:
- A retrospective analysis of lung cancer cases from 2021-2022 was performed.
- A unique case of SCLC with a SYN2-PPARG gene fusion was identified.
- The patient was a 60-year-old female smoker with advanced, metastatic SCLC.
Findings:
- Histopathological analysis confirmed SCLC with a neuroendocrine phenotype and high proliferation.
- Next-generation sequencing revealed a novel SYN2-PPARG fusion.
- This fusion has been previously reported in sinonasal adenocarcinoma and one prior SCLC case.
Implications:
- The discovery of the SYN2-PPARG fusion underscores the molecular heterogeneity of SCLC.
- Understanding such unique genetic alterations may facilitate the development of targeted therapies.
- This finding could contribute to personalized treatment strategies for SCLC patients.
More Related Videos
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
